Central Nervous System
PV QA 2 - Poster Viewing Q&A 2
MO_5_2583 - Proton beam re-irradiation as salvage therapy for recurrent intracranial meningiomas
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
Proton beam re-irradiation as salvage therapy for recurrent intracranial meningiomas
B. S. Imber1, D. L. Casey2, B. Neal3, H. Darwish3, O. Cahlon1, E. B. Hug3, H. K. Tsai3, B. H. Chon3, Y. Yamada2, and T. J. Yang2; 1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3ProCure Proton Therapy Center, Somerset, NJ
Purpose/Objective(s): Recurrent meningiomas remain a therapeutic challenge, often progressive despite multimodality salvage therapy. While radiation therapy is a well-accepted treatment in the upfront setting, there is limited data guiding re-irradiation (reRT) for recurrent disease. Proton beam radiotherapy (PBRT) offers a potential advantage for reRT due to the ability to better spare previously irradiated tissue. We sought to analyze PBRT reRT outcomes.
Materials/Methods: A retrospective review was performed of 16 consecutive patients who received PBRT reRT for recurrent meningiomas between 2013–2017. Kaplan-Meier estimate was used to determine intracranial control (IC) and overall survival (OS) following PBRT. Clinical predictors of IC and OS, including demographics, tumor grade, duration between previous RT and PBRT, PBRT dose and planning target volume (PTV) were evaluated using Cox regression analysis. Toxicity was graded according to NCI CTCAE version 4.
Results: The median age of the cohort was 62 years (range 28-84). All patients were diagnosed pathologically. At initial diagnosis, 7 (44%), 8 (50%) and 1 (6%) patients had WHO grade I, II and III tumors, respectively. At time of PBRT reRT, 5 patients developed transformed disease, resulting in 4 (25%), 8 (50%) and 4 (25%) patients with grade I, II and III tumors, respectively. All patients received prior RT to a median of 54 Gy (range 13-65.5). The median time to PBRT reRT after prior RT was 5.8 years (range 0.7-18.7). The median PBRT dose was 60 Gy (RBE) (range 30-66.6), and the median PTV was 76 cm3 (range 8-249). At last follow up, 7 intracranial recurrences (44%) and 3 disease-related deaths (19%) were found. The median follow-up was 13.9 months (range 1-33). Median IC for the cohort was 18.8 months, with 1 and 2-year IC of 75% and 20%, respectively. Median OS after PBRT was not achieved with 1 and 2-year OS of 93% and 61%. Patients with initial grade I tumors had significantly improved IC after PBRT reRT compared to higher grade (HR= 0.25, p=0.04), however pathologic grade at the time of reRT was not predictive of IC. Greater duration of time between the prior course of RT and PBRT reRT was also significantly associated with improved IC (HR= 0.6, p=0.04). PBRT reRT dose and PTV size were not found to be associated with IC. No clinical predictors of OS were identified. Two (13%) patients developed radionecrosis at 6 and 16 months after completion of PBRT reRT: one patient had asymptomatic radiation necrosis that did not require medical intervention and one patient underwent surgical resection for symptomatic radiation necrosis.
Conclusion: This is the first retrospective series specifically analyzing the role of PBRT reRT for recurrent meningioma. We found promising intracranial control can be achieved with low rate of radiation necrosis at 1 year after PBRT reRT. However, strategies to achieve durable intracranial control are needed in this patient population, particularly for patients with high-grade tumors.
Author Disclosure: B.S. Imber: None. B. Neal: None. O. Cahlon: None. E.B. Hug: None. Y. Yamada: Speaker's Bureau; Institute for Medical Education, Varian Medical Systems, BrainLab.